Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 3/19/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Mark S. Kipnes M.D.

Wrong Dr. Mark S. Kipnes M.D.?

Executive Vice President, Medical...

Phone: (210) ***-****  
Email: m***@***.com
Local Address:  San Antonio , Texas , United States
Cetero Research company
10550 Rockley Road Ste. 150
Houston , Texas 77099
United States

Company Description: Cetero Research is a privately held clinical research company, specializing in a broad range of Phase I , IV drug testing. The Cetero , St. Louis site is in the...   more

Employment History

Board Memberships and Affiliations


  • M.D.
    Gothenburg University
64 Total References
Web References
Versartis, Inc. - Clinical Advisors, 19 Mar 2014 [cached]
Mark Kipnes, M.D., Executive Vice President, Medical Affairs, Cetero Research/DGD Research
Diartis Pharmaceuticals - Clinical Advisors, 26 Dec 2013 [cached]
Mark Kipnes, M.D., Executive Vice President, Medical Affairs, DGD Research
Researchers make headway on oral, nasal insulin, 16 July 2001 [cached]
In announcing the results of Nobex Corp.'s phase II studies of its fast-acting oral insulin , Mark Kipnes , M.D. , an endocrinologist at the Diabetes and Glandular Disease Clinic in San Antonio , said the product controlled blood glucose with lower levels of insulin in the peripheral circulation than is the case with injectable insulin.
Meanwhile , the insulin sensitizer rosiglitazone ( Avandia , GlaxoSmithKline ) reduced inflammatory mediators such as C-reactive protein , which are associated with the development of atherosclerosis , in a group of 11 nondiabetic but obese patients in a study by Paresh Dandona , M.D. , of the University of Buffalo.The study thus demonstrates that rosiglitazone may be effective in preventing cardiovascular disease in people without diabetes.
Other reports at the meeting also centered on lowering insulin resis-tance to try to prevent the onset of Type 2 diabetes.
OnMedica - Diabetic nerve therapy shows 'striking' results, 10 Sept 2004 [cached]
Dr Mark Kipnes, a clinical investigator for Sangamo and endocrinologist at the clinic, said: "Currently, there are no effective therapies available to treat this debilitating and frequent complication of diabetes and patients are generally prescribed painkillers to alleviate symptoms.
"Existing treatments for diabetic ..., 1 Jan 2006 [cached]
"Existing treatments for diabetic neuropathy are limited to the use of anti-depressants, analgesics or other agents for the management of pain," commented Mark Kipnes, M.D., a principal clinical investigator for Sangamo and Endocrinologist at the Diabetes and Glandular Disease Clinic in San Antonio, Texas.
Other People with the name "Kipnes":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.